A1 Refereed original research article in a scientific journal

Clearance of Chlamydia pneumoniae infection in H-2 class I human leucocyte antigen-A2.1 monochain transgenic mice




AuthorsTammiruusu A, Haveri A, Pascolo S, Lahesmaa R, Stevanovic S, Rammensee HG, Sarvas M, Puolakkainen M, Vuola JM

Publication year2005

JournalScandinavian Journal of Immunology

Journal name in sourceScandinavian journal of immunology

Journal acronymScand J Immunol

Volume62

Issue2

First page 131

Last page9

Number of pages9

ISSN0300-9475

DOIhttps://doi.org/10.1111/j.1365-3083.2005.01645.x(external)


Abstract
CD8+ T cells have been suggested to play an important role in protective immunity against pulmonary Chlamydia pneumoniae infection in mice. Moreover, several classical major histocompatibility complex class I - restricted cytotoxic CD8+ T lymphocytes (CTL) specific for C. pneumoniae- derived peptides have been identified. Here, we studied the outcome of C. pneumoniae infection in human leucocyte antigen (HLA)-A2.1 transgenic mice (HHD mice) that are only able to express a classical human class I molecule (HLA-A2.1). C. pneumoniae infection was self-restricted in HHD mice which were able to develop specific immune responses and a protective immunity against a subsequent rechallenge in a manner comparable to wildtype mice. Furthermore, accumulation of functional and C. pneumoniae-specific T cells to the site of infection was detected after challenge. Antigen processing and HLA-A2.1-dependent presentation was studied by immunizing the HHD mice with chlamydial outer protein N (CopN). Isolation of a peptide-specific CTL line from the CopN-immunized mice suggests that the HLA-A2.1 molecule can support the development of CTL response against a chlamydial protein in mice. These findings suggest that the transgenic mouse model can be used for further characterization of the HLA-A2.1-restricted CD8+ T-cell response during C. pneumoniae infection and for identification of CD8 epitopes from chlamydial antigens.



Last updated on 2024-26-11 at 11:20